Keam Susan J
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Am J Cardiovasc Drugs. 2025 Jan;25(1):1-6. doi: 10.1007/s40256-024-00718-5.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
氟吡达唑F 18（FLYRCADO™）是通用电气医疗集团（GE Healthcare）和朗泰斯医疗成像公司（Lantheus Medical Imaging）正在研发的一种静脉注射放射性诊断药物，用于正电子发射断层扫描（PET）心肌灌注成像（MPI）以检测冠状动脉疾病（CAD）。2024年9月，氟吡达唑F 18在美国被批准用于已知或疑似CAD的成年患者在静息或负荷状态（药物负荷或运动负荷）下的PET MPI，以评估心肌缺血和梗死情况。本文总结了氟吡达唑F 18研发过程中的重要节点，这些节点促成了其首次获批用于成年患者的PET MPI以评估心肌缺血和梗死。
